Thermo Fisher Scientific recently launched the Thermo Scientific Vulcan™ Automated Lab, a cutting-edge solution designed to enhance semiconductor manufacturing processes. The launch focuses on bridging critical gaps in transmission electron microscopy metrology, supporting the semiconductor industry's growing demands. Despite this innovation, TMO's share price declined by 1.37% over the last week. This price move aligns with broader market trends, as major indices like the Nasdaq Composite and the S&P 500 saw declines due to economic uncertainties and a mixed performance in the tech sector, including Nvidia's notable fluctuations during its GTC Conference. The general market environment, reflected in a 0.8% drop in the Dow Jones Industrial Average, coupled with substantial declines in individual tech stocks such as Tesla and Alphabet, demonstrates a sector-wide impact likely affecting TMO's share performance. This broader economic context provides valuable insights into TMO's recent price movement despite its innovative product advancements.

Understand Thermo Fisher Scientific's track record by examining our performance history report.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Over the past five years, Thermo Fisher Scientific's total shareholder return, including dividends, was 105.99%, indicating a substantial investment gain. During this period, the company effectively leveraged product expansion and infrastructure investment to capitalize on emerging needs, particularly within COVID-19 diagnostics. Launches like the CE-IVD-Marked TaqPath COVID-19 HT Kit in early 2021 supported this growth trajectory. Furthermore, expansions such as the Lenexa, Kansas facility dedicated to COVID-19 testing media underscored the company's adaptability to public health demands.

The company's robust dividend payouts, exemplified by increases as recent as February 2025, combined with strategic share repurchases totaling $3 billion in early 2025, served to bolster shareholder returns. However, despite these positive strides, Thermo Fisher's one-year return lagged behind the US market's 10% benchmark, though it outpaced its own industry, which saw declines. Such a mixed performance highlights both the resilience and challenges faced in a competitive landscape.

Are you invested in Thermo Fisher Scientific already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:TMO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com